CV
CV.US CapsoVision, Inc. Common Stock
- Market cap
- USD 321M
- P/E
- -
- P/B
- 25.42x
- ROE
- -110.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CV.US undervalued?
Graham numberThe Graham number of CapsoVision, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CapsoVision, Inc. Common Stock fundamental analysis
No fundamental analysis for CapsoVision, Inc. Common Stock yet.
CapsoVision, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CapsoVision, Inc. Common Stock
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It al…
Full company profileCapsoVision, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CapsoVision, Inc. Common Stock annual financial statements
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 9.75M | 11.8M | 13.6M | 13.3M |
| Gross Profit | 5.49M | 6.38M | 7.17M | 6.62M |
| Operating Income | -11.3M | -19.9M | -25.5M | -29.4M |
| EBITDA | -11.0M | -19.4M | -24.9M | -28.7M |
| Net Income | -11.3M | -19.9M | -25.3M | -29.1M |
| EPS | -0.29 | -0.43 | -0.54 | -0.58 |
| Balance Sheet | ||||
| Total Assets | 21.5M | 16.8M | 18.2M | 32.8M |
| Total Liabilities | 131M | 146M | 4.90M | 6.38M |
| Shareholders' Equity | -110M | -130M | 13.3M | 26.4M |
| Cash & Short-term Investments | 14.6M | 9.32M | 10.1M | 21.8M |
| Total Debt | 1.51M | 1.24M | 887K | 780K |
| Cash Flow | ||||
| Operating Cash Flow | -10.8M | -20.1M | -22.9M | -28.7M |
| Capital Expenditure | 754K | 153K | 90.0K | 93.3K |
| Free Cash Flow | -11.6M | -20.2M | -23.0M | -28.8M |
| Ratios | ||||
| ROE | - | - | -190.9% | -110.5% |
| ROA | -52.5% | -118.4% | -139.4% | -89.0% |
| Net Profit Margin | -115.9% | -169.3% | -186.8% | -218.5% |
| Debt to Equity | - | - | 0.07x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CapsoVision, Inc. Common Stock dividends
CapsoVision, Inc. Common Stock has not paid dividends in the last 3 fiscal years.
Who owns CapsoVision, Inc. Common Stock
- Insiders 33.74%
- Institutions 10.71%
- Public & others 55.55%
- Shares outstanding 53.2M
- Free float 30.0M
Top funds holding CV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 925K | 1.74% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 826K | 1.55% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 383K | 0.72% | +0.54% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 331K | 0.62% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 203K | 0.38% | +1.67% | Sep 2026 |
| Fidelity Extended Market Index | 164K | 0.31% | +288.81% | Sep 2026 |
| iShares Micro-Cap ETF | 105K | 0.20% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 85.0K | 0.16% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 77.4K | 0.15% | +423.01% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 65.2K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 60.2K | 0.11% | +356.99% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 46.0K | 0.09% | 0.00% | Aug 2026 |
| Bridge Builder Small Cap Fund | 41.4K | 0.08% | +677.12% | Oct 2026 |
| Vanguard Russell 2000 Growth ETF | 38.7K | 0.07% | 0.00% | Sep 2026 |
| EQ/2000 Managed Volatility IB | 37.5K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth Index | 34.6K | 0.07% | +1.03% | Aug 2026 |
| Xtrackers Russell 2000 ETF 1C | 29.9K | 0.06% | -6.31% | Sep 2026 |
Top institutions holding CV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 1.90M | 3.56% | +45.36% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.06M | 1.99% | +3.14% | Jun 2026 |
| Geode Capital Management, LLC | 578K | 1.09% | +32.94% | Jun 2026 |
| State Street Corp | 410K | 0.77% | +60.22% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 240K | 0.45% | +46.26% | Jun 2026 |
| Northern Trust Corp | 220K | 0.41% | +44.48% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 104K | 0.19% | +16.92% | Jun 2026 |
| Charles Schwab Investment Management Inc | 79.4K | 0.15% | +29.30% | Jun 2026 |
| Bank of New York Mellon Corp | 75.0K | 0.14% | +52.19% | Jun 2026 |
| Nuveen, LLC | 46.0K | 0.09% | +39.01% | Jun 2026 |
| Deutsche Bank AG | 34.7K | 0.07% | +37.21% | Jun 2026 |
| XTX Topco Ltd | 31.8K | 0.06% | -52.74% | Jun 2026 |
| Wells Fargo & Co | 31.8K | 0.06% | +210.59% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 29.0K | 0.05% | +48.47% | Jun 2026 |
| Bank of America Corp | 25.5K | 0.05% | +14.53% | Jun 2026 |
| Rhumbline Advisers | 22.0K | 0.04% | +67.29% | Jun 2026 |
| MetLife Investment Management, LLC | 21.1K | 0.04% | +26.39% | Jun 2026 |
| Amvescap Plc. | 18.8K | 0.04% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 18.7K | 0.04% | +25.35% | Jun 2026 |
| The Goldman Sachs Group Inc | 18.6K | 0.04% | -48.42% | Jun 2026 |
CapsoVision, Inc. Common Stock company profile
- Company name
- CapsoVision, Inc. Common Stock
- Ticker
- CV.US
- Exchange
- USA Stocks
- Listed since
- Jul 2, 2025
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 99
- Fiscal year end
- December
- Address
- 18805 Cox Avenue, Saratoga, CA, United States, 95070
- Phone
- 408 624 1488
- Website
- capsovision.com
About CapsoVision, Inc. Common Stock
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
CapsoVision, Inc. Common Stock management
5- Mr. Kang-Huai WangCo-Founder, President, CEO & Director · born 1957
- Mr. David GarciaCompliance Officer, SVP of Finance, Principal Financial & Accounting Officer · born 1975
- Mr. Douglas AtkinsonSenior Vice President of Global Sales · born 1968
- Helen ChauManager of Human Resources
- Anna KrylovaCorporate Controller